Cargando…
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantia...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712735/ https://www.ncbi.nlm.nih.gov/pubmed/24213503 http://dx.doi.org/10.3390/cancers4041161 |